JHOP - April 2021 Vol 11, No 2

Facial Edema Preceding Acute Renal Injury Linked to Pemetrexed Therapy in a Patient with Lung Cancer

Matthew S. Mattila, PharmD, BCPS, BCOP; Joel H. Lundberg, MD, FACP

Assessment of High-Dose Methotrexate Management Guideline in Adults with Cancer at an Academic Medical Center

Andrew Kowalski, PharmD, BCOP; Sara Mohamed Jaszczur, PharmD, BCOP; Michelle Nadeau-Nguyen, PharmD, BCPS; Man Yee Merl, PharmD, BCOP

Comparison of Direct Oral Factor Xa Inhibitors versus Warfarin for the Treatment of Venous Thromboembolism in Obese or Overweight Patients: A Retrospective Analysis

Jennifer C. Cook, PharmD; Tracy E. Wiczer, BCOP, PharmD; Anthony T. Gerlach, PharmD, FCCM, FCCP; Caitlin Linger, PharmD; Meghan E. Ritchey, PharmD Candidate; Bridgette M. Zickefoose, PharmD; Tzu-Fei Wang, MD; Kristin I. Brower, BCPS, PharmD

Review Article

Biomarker-Driven Targeted Therapies in Solid Tumor Malignancies

Hanjie Mo, PharmD, BCOP; Catherine Renna, PharmD, BCOP

Overcoming Resistance: Antibiotic Guidance for Multidrug-Resistant Febrile Neutropenia in Patients with Cancer

Sonya K. Kedzior, PharmD; YoungYoon Ham, PharmD; Joseph Bubalo, PharmD, BCOP, BCPS

From the Literature

Oral Azacitidine Prolongs Survival in Patients with Acute Myeloid Leukemia

Enfortumab Vedotin Superior to Chemotherapy in Urothelial Cancer

Low-Dose Capecitabine Maintenance Therapy Improves Survival in Patients with Triple-Negative Breast Cancer

FDA Updates

Yescarta First CAR T-Cell Therapy Approved for Follicular Lymphoma

Libtayo Receives 2 New Indications: For Basal-Cell Carcinoma and for NSCLC

Abecma First CAR T-Cell Therapy Approved for Multiple Myeloma

FDA Approved Pepaxto for Relapsed or Refractory Multiple Myeloma

Cosela First CDK4/6 Inhibitor FDA Approved to Reduce Chemotherapy-Induced Myelosuppression

FDA Approved Breyanzi, Novel CAR T-Cell Therapy, for Large B-Cell Lymphoma

Ukoniq, New Targeted Therapy, FDA Approved for Marginal-Zone and Follicular Lymphoma